Evidence map›Paper›PMID 28866778›Full record

SynthesisPharmacoEconomics2018

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.

Samuel Herzog, Marian Shanahan, Peter Grimison, Anh Tran, Nicole Wong, Nicholas Lintzeris, John Simes, Martin Stockler, Rachael L Morton

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in PharmacoEconomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?Clinical medicine insights. Arthritis and musculoskeletal disorders · 2021
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Samuel HerzogSydney Medical School, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 2006, Australia.
Marian ShanahanNational Drug and Alcohol Research Centre, The University of New South Wales, Sydney, NSW, 2052, Australia.
Peter GrimisonChris O'Brien Lifehouse, Camperdown, NSW, 2050, Australia.
Anh TranSydney Medical School, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 2006, Australia.
Nicole WongSydney Medical School, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 2006, Australia.
Nicholas LintzerisDiscipline of Addiction Medicine, The University of Sydney, Camperdown, NSW, 2006, Australia.
John SimesSydney Medical School, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 2006, Australia.
Martin StocklerSydney Medical School, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 2006, Australia.
Rachael L MortonSydney Medical School, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, 2006, Australia. rachael.morton@ctc.usyd.edu.au.ORCID 0000-0001-7834-0572
The University of Sydney · AUChris O’Brien Lifehouse · AUUNSW Sydney · AU

Funding

Cancer Australia 1129568National Health and Medical Research Council 1054216
6 · The paper itself

Abstract

introductionCannabis-based medicines (CBMs) may offer relief from symptoms of disease; however, their additional cost needs to be considered alongside their effectiveness. We sought to review the economic costs and benefits of prescribed CBMs in any chronic illness, and the frameworks used for their economic evaluation.

methodsA systematic review of eight medical and economic databases, from inception to mid-December 2016, was undertaken. MeSH headings and text words relating to economic costs and benefits, and CBMs were combined. Study quality was assessed using relevant checklists and results were synthesised in narrative form.

resultsOf 2514 identified records, ten studies met the eligibility criteria, all for the management of multiple sclerosis (MS). Six contained economic evaluations, four studies reported utility-based quality of life, and one was a willingness-to-pay study. Four of five industry-sponsored cost-utility analyses for MS spasticity reported nabiximols as being cost-effective from a European health system perspective. Incremental cost-effectiveness ratios per quality-adjusted life-year (QALY) gained for these five studies were £49,257 (UK); £10,891 (Wales); €11,214 (Germany); €4968 (Italy); and dominant (Spain). Nabiximols for the management of MS spasticity was not associated with statistically significant improvements in EQ-5D scores compared with standard care. Study quality was moderate overall, with limited inclusion of both relevant societal costs and discussions of potential bias.

conclusionsPrescribed CBMs are a potentially cost-effective add-on treatment for MS spasticity; however, this evidence is uncertain. Further investment in randomised trials with in-built economic evaluations is warranted for a wider range of clinical indications. SYSTEMATIC REVIEW REGISTRATION: PROSPERO Registration Number: CRD42014006370.

Indexed as

Quality of LifeChronic DiseaseCost-Benefit AnalysisHumansMedical MarijuanaMultiple SclerosisQuality-Adjusted Life YearsMedical Marijuana

Identifiers

PMID28866778
OpenAlexW2751676254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.